Damien M. Rasmussen

Damien M. Rasmussen

Auto-generated profile, based on publicly available information

Damien M. Rasmussen

Department of Pharmacology, University of Minnesota

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ELEric W. Lake
Eric W. Lake
JMJoseph M. Muretta
Joseph M. Muretta
ATAndrew R. Thompson
Andrew R. Thompson
DRDamien M. Rasmussen
Damien M. Rasmussen
AMAbir Majumdar
Abir Majumdar
NLNicholas M. Levinson
Nicholas M. Levinson
Significance: Many drugs trigger changes to the structure of their target receptor upon binding. These conformational effects are thought to be an essential part of molecular recognition but have proven challenging to quantify. Using a high-throughput method for tracking structural changes in a protein kinase in solution, we discovered that many clinically important cancer drugs trigger substantial structural changes to their target protein kinase Aurora A, and that these effects systematically account for the ability of the drugs to differentiate between different biochemical forms of Aurora A. The results provide insight into mechanisms of drug selectivity and suggest strategies for tailoring inhibitors to target certain cancers in which Aurora A has been dysregulated in different ways.

3 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EFErik B. Faber
Erik B. Faber
LSLuxin Sun
Luxin Sun
JTJian Tang
Jian Tang
EREmily Roberts
Emily Roberts
SGSornakala Ganeshkumar
Sornakala Ganeshkumar
GGGunda I Georg
Gunda I Georg
Compared to most ATP-site kinase inhibitors, small molecules that target an allosteric pocket have the potential for improved selectivity due to the often observed lower structural similarity at these distal sites. Despite their promise, relatively few examples of structurally confirmed, high-affinity allosteric kinase inhibitors exist. Cyclin-dependent kinase 2 (CDK2) is a target for many therapeutic indications, including non-hormonal contraception. However, an inhibitor against this kinase with exquisite selectivity has not reached the market because of the structural similarity between CDKs. In this paper, we describe the development and mechanism of action of type III inhibitors that bind CDK2 with nanomolar affinity. Notably, these anthranilic acid inhibitors exhibit a strong negative cooperative relationship with cyclin binding, which remains an underexplored mechanism for CDK2 inhibition. Furthermore, the binding profile of these compounds in both biophysical and cellular assays demonstrate the promise of this series for further development into a therapeutic selective for CDK2 over highly similar kinases like CDK1. The potential of these inhibitors as contraceptive agents is seen by incubation with spermatocyte chromosome spreads from mouse testicular explants, where they recapitulate Cdk2-/- and Spdya-/- phenotypes.

1 February 2021 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
AMAbir Majumdar
Abir Majumdar
DBDavid J. Burban
David J. Burban
JMJoseph M. Muretta
Joseph M. Muretta
ATAndrew R. Thompson
Andrew R. Thompson
TETiffany A. Engel
Tiffany A. Engel
NLNicholas M. Levinson
Nicholas M. Levinson

14 May 2024 in eLife
Verified
Journal Article
Open access
DRDamien M Rasmussen
Damien M Rasmussen
MSManny M Semonis
Manny M Semonis
JGJoseph T Greene
Joseph T Greene
JMJoseph M Muretta
Joseph M Muretta
ATAndrew R Thompson
Andrew R Thompson
NLNicholas M Levinson
Nicholas M Levinson
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation, we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.

1 December 2018 in Journal of Structural Biology
Verified
Journal Article
Closed access
DRDamien M. Rasmussen
Damien M. Rasmussen
RSRoss W. Soens
Ross W. Soens
TDTimothy J. Davie
Timothy J. Davie
CVCody K. Vaneerd
Cody K. Vaneerd
BBBasudeb Bhattacharyya
Basudeb Bhattacharyya
JMJohn F. May
John F. May

19 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
DRDamien M. Rasmussen
Damien M. Rasmussen
MSManny M. Semonis
Manny M. Semonis
JGJoseph T. Greene
Joseph T. Greene
JMJoseph M. Muretta
Joseph M. Muretta
ATAndrew R. Thompson
Andrew R. Thompson
NLNicholas M. Levinson
Nicholas M. Levinson
The type II class of RAF inhibitors currently in clinical trials paradoxically activate BRAF at subsaturating concentrations. Activation is mediated by induction of BRAF dimers, but why activation rather than inhibition occurs remains unclear. Using biophysical methods tracking BRAF dimerization and conformation we built an allosteric model of inhibitor-induced dimerization that resolves the allosteric contributions of inhibitor binding to the two active sites of the dimer, revealing key differences between type I and type II RAF inhibitors. For type II inhibitors the allosteric coupling between inhibitor binding and BRAF dimerization is distributed asymmetrically across the two dimer binding sites, with binding to the first site dominating the allostery. This asymmetry results in efficient and selective induction of dimers with one inhibited and one catalytically active subunit. Our allosteric models quantitatively account for paradoxical activation data measured for 11 RAF inhibitors. Unlike type II inhibitors, type I inhibitors lack allosteric asymmetry and do not activate BRAF homodimers. Finally, NMR data reveal that BRAF homodimers are dynamically asymmetric with only one of the subunits locked in the active αC-in state. This provides a structural mechanism for how binding of only a single αC-in inhibitor molecule can induce potent BRAF dimerization and activation.